Pfizer (NYSE_PFE) Discontinues Danuglipron Development After Safety Review in Study
2025-04-14 17:23
https://finance.yahoo.com/news/pfizer-nyse-pfe-discontinues-danuglipron-172306284.html?.tsrc=rss
Oops, something went wrongTip: Try a valid symbol or a specific company name for relevant resultsOops, something went wrongTrump is wrecking his own economic agendaHigher clothing costs from tariffs are coming soon — but not immediately, experts sayWhy Tesla, GM, and Rivian will be hurt most by China's critical minerals export banTrump says he's 'looking at something' to help car companies with tariffsStocks rally for second straight day, while Apple jumps on tech tariff reprieveThe Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon tradingAmericans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey foundStocks surge as Apple leads way higher after tech's tariff reprieveTrump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bendGoldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slowsCorporate earnings take center stage amid tariff turmoil: What to know this weekTrump has tariffs, taxes, and the debt ceiling on a collision course for this summerTrump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg)Tax day 2025 is coming up. Here’s what to know to file by the deadline.Commentary: Put the P/E ratio in timeout for nowMarket chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landingApple was on brink of crisis before tariff concession from Trump (Bloomberg)Corporate earnings take center stage amid tariff turmoil: What to know this weekThe best (and worst) time of year to buy a houseThe Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg)How to invest in gold in 4 stepsChanging jobs can disrupt saving for retirement. Here's how to stay on track.Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg)Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard ofThe tariff uncertainty isn't getting any better in markets: Chart of the Week'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflationGold notches best week since 2020 amid 'shaken' investor confidence in USThe bond market just had one of its most volatile and unusual weeks in recent memoryStocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains.The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market.Consumer sentiment craters further as inflation expectations soar to highest since 1981Dow, S&P 500, Nasdaq slide as China hits US with tariff hike, bank earnings roll inJPMorgan's Dimon says economy is facing 'considerable turbulence'Tariff uncertainty muddies — and refocuses — earnings seasonChina raises tariffs on US goods to 125% from the 84% planned in response to Trump's latest hikeChina already knows Trump's breaking point in their burgeoning trade war, our columnist writesHow the bond market helped make Trump blink on tariffsThe Dow fell 1,000 points, and the S&P 500 and Nasdaq were crushed as stocks resumed a tariff-fueled sell-offTrump's total tariff on China is actually 145%, the White House said, an amount higher than the 125% previously reportedStocks hit session lows as focus turned to the US-China trade war. The Dow lost over 1,200 points, and the Nasdaq plunged 4.5%.The Dow plummeted 900 points and the Nasdaq plunged over 3% as a tariff-fueled sell-off picked up speed again.Stocks plummet as Wall Street's euphoria from Trump's tariff pause gets a reality checkInflation unexpectedly tumbled in March, and core CPI rose at its slowest pace in four years.The EU matched Trump's 90-day pause on tariffs to 'give negtiations a chance.' See our live updates.The 'Trump put' makes an appearanceMarch's report could be last time investors see inflation easing. Here's what to expect.Stocks wanted one thing from Trump after his shocking tariff announcement last week. They finally got it today.Stocks staged a wild rally after Trump's tariff reversal. The Dow gained near 3,000 points and the S&P 500 had its best day since 2008.Trump nodded to market turbulence as a factor in his 'reciprocal' tariff pause, saying investors were 'yippy' and 'afraid'Unlock stock picks and a broker-level newsfeed that powers Wall Street.Pfizerrecently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in its share price over the past week. This move was primarily due to safety concerns in clinical studies. Despite achieving key pharmacokinetic goals, the discovery of a potential drug-induced liver injury prompted Pfizer to reassess its strategy. This decision adds weight to the company's stock performance, contrasting with broader market trends, where major indexes experienced upward movement amidst tariff-related developments and positive gains in tech sectors. Pfizer's decision highlights the importance of rigorous safety evaluations in pharmaceutical developments.We've discovered 3 warning signs for Pfizer (2 are significant!) that you should be aware of before investing here.Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.The cessation of Danuglipron’s development could significantly influence Pfizer's revenue and earnings forecasts moving forward. By prioritizing rigorous safety measures, Pfizer may face setbacks in accelerating R&D productivity and the associated revenue streams. This shift may lead to a more conservative approach in pipeline-driven growth expectations and could delay anticipated financial impacts from new products, potentially further pressuring revenue forecasts already impacted by legislative changes. The development halt aligns with observed market volatility around Pfizer shares, shedding light on investor concerns regarding the company's future earning capabilities amidst evolving challenges in the pharmaceutical sector.Over the past year, Pfizer's total return, including dividends, was a 10.14% decline, signaling underperformance relative to both the broader market and the US Pharmaceuticals industry, which experienced negative returns of 8.6%. During this period, the company's earnings showed considerable growth from a very low base, yet they have not matched market expectations overall. Notably, analysts have set a fair value price target of US$26.02, suggesting upside potential compared to the current share price of US$22.49. However, this assumes improvements in profit margins and financial performance that are not without risk given current operational challenges and headwinds from pricing reforms in Medicare.Understand Pfizer's track record by examining our performance history report.This article by Simply Wall St is general in nature.We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Companies discussed in this article includeNYSE:PFE.Have feedback on this article? Concerned about the content?Get in touchwith us directly.Alternatively, emaileditorial-team@simplywallst.comPfizer Inc. will stop developing an obesity pill after the treatment was linked to a potentially drug-related liver injury in a clinical trial patient. The company won't advance the once-daily medicine into the final stage of testing and will instead invest in earlier-stage treatments for obesity. Damian Garde reports on Bloomberg Television.Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial.Pfizer ends its most advanced clinical trial of an obesity pill to compete in the hot GLP-1 space.The Dow Jones rose on the stock market today and auto stocks popped after President Donald Trump spoke out. Palantir stock was higher while Nvidia fell.How much does the radio host expect you to invest each year?Retiring on a fixed income can seem daunting, but with some planning and commitment to a frugal lifestyle, it's possible to retire comfortably on $2,000 a month. This takes discipline but ultimately...United Wholesale Mortgage claims the top spot on the latest list.It is very rare for an ordinary household to owe money on gifts. The gift tax has a somewhat complicated two-tier structure. Each year you can give up to an annual amount (the "annual exclusion") without paying, or even reporting, anything on your taxes. Then, over your lifetime, you have a significantly higher amount that […] The post I Want to Give $65k to My Daughter and Her Husband. Will We Have to Pay Taxes? appeared first on SmartReads by SmartAsset.If you’re making $275,000 a year, you can't contribute to a Roth IRA due to income limits. However, a backdoor conversion can allow a high earner to sock away unlimited sums in a Roth account, enabling tax-free requirement withdrawals and a way past pesky required minimum distribution rules (RMDs) that many pretax retirement account require. […] The post I’m Earning $275k This Year. Can I Use a Backdoor Roth Strategy to Reduce Taxes? appeared first on SmartReads by SmartAsset.These stocks have a record of strong growth and several offer a dividend.Tip: Try a valid symbol or a specific company name for relevant resultsSign in to access your portfolioTry again.